That the mere lack of p53 protein is insufficient to render GSC-driven tumors more susceptible to ClQ-mediated radiosensitization supports the view that specific activities of p53 mutant proteins should be taken into consideration when assessing the actionability of anti-cancer treatments [83]. Here, TP53 is linked to cancer.